Explore more publications!
Djibouti Health Journal
Submit Press Release

Djibouti Health Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Djibouti Health Journal.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on November 3, 2025

FDA Approves KYGEVVI® (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare and Devastating Mitochondrial Disease
November 3, 2025

FDA Approves KYGEVVI® (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare and Devastating Mitochondrial Disease

Indeterminate GlobeNewswire
Flo Health and Dr. Sameena Rahman Address Perimenopause and Its Workplace Impact with YourUpdateTV
November 3, 2025

Flo Health and Dr. Sameena Rahman Address Perimenopause and Its Workplace Impact with YourUpdateTV

Indeterminate GlobeNewswire
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
November 3, 2025

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Indeterminate GlobeNewswire
Sanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial Results
November 3, 2025

Sanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial Results

Indeterminate GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 3, 2025

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU
November 3, 2025

Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU

Indeterminate GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
November 3, 2025

Olema Oncology to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025
November 3, 2025

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025

Indeterminate GlobeNewswire
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th
November 3, 2025

NANOBIOTIX to Participate in Investor Conferences the Week of November 10th

Indeterminate GlobeNewswire
Castle Biosciences Reports Third Quarter 2025 Results
November 3, 2025

Castle Biosciences Reports Third Quarter 2025 Results

Indeterminate GlobeNewswire
Nyxoah to Participate in the Stifel 2025 Healthcare Conference
November 3, 2025

Nyxoah to Participate in the Stifel 2025 Healthcare Conference

Indeterminate GlobeNewswire
Nyxoah Participera à la Conférence Stifel Healthcare 2025
November 3, 2025

Nyxoah Participera à la Conférence Stifel Healthcare 2025

Indeterminate GlobeNewswire
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
November 3, 2025

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis

Indeterminate GlobeNewswire
Option Care Health to Participate in Upcoming Investor Conferences
November 3, 2025

Option Care Health to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire
Pyxis Oncology to Participate in Upcoming Investor Conferences
November 3, 2025

Pyxis Oncology to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire
BeautyHealth Appoints Philippe Schaison, PharmaD, to Board of Directors
November 3, 2025

BeautyHealth Appoints Philippe Schaison, PharmaD, to Board of Directors

Indeterminate GlobeNewswire
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®
November 3, 2025

Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®

Indeterminate GlobeNewswire
BBOT to Participate in the Jefferies Global Healthcare Conference in London
November 3, 2025

BBOT to Participate in the Jefferies Global Healthcare Conference in London

Indeterminate GlobeNewswire
Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis
November 3, 2025

Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

Indeterminate GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 3, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions